• +1-646-491-9876
    • +91-20-67278686

    Search

    Warts - Pipeline Review, H1 2017

    Warts - Pipeline Review, H1 2017

    • Report Code ID: RW0001689454
    • Category Healthcare
    • No. of Pages 81
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H1 2017, provides an overview of the Warts (Infectious Disease) pipeline landscape.

    Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Warts - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 15, 1, 6 and 3 respectively.

    Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).
    - The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Warts - Overview
    Warts - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Warts - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Warts - Companies Involved in Therapeutics Development
    3M Drug Delivery Systems
    Aclaris Therapeutics Inc
    Agilvax Inc
    Aviragen Therapeutics Inc
    Biogenomics Ltd
    BioMAS Ltd
    Cutanea Life Sciences Inc
    Cytovation AS
    Foamix Pharmaceuticals Ltd
    G&E Herbal Biotechnology Co Ltd
    Laboratories Ojer Pharma SL
    LEO Pharma A/S
    Nielsen Biosciences Inc
    Novan Inc
    Novartis AG
    Promius Pharma LLC
    RXi Pharmaceuticals Corp
    Tamir Biotechnology Inc
    Verrica Pharmaceuticals Inc
    Zydus Cadila Healthcare Ltd
    Warts - Drug Profiles
    (digoxin + furosemide) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    854-A - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Albicin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AX-03 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BTA-074 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CB-0602 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CyPep-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DFD-05 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FIT-039 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    furosemide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    human papillomavirus vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    hydrogen peroxide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    imiquimod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    imiquimod SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ingenol mebutate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    interferon alfa-2b - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LFX-453 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    omiganan pentahydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    povidone iodine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PP-210 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ranpirnase - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Samcyprone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SB-206 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SRT-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VP-100 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Warts - Dormant Projects
    Warts - Discontinued Products
    Warts - Product Development Milestones
    Featured News & Press Releases
    Nov 29, 2016: Novan Announces Statistically Significant Phase 2 Clinical Trial Results for SB206
    Aug 18, 2016: Aclaris Therapeutics Announces Positive Results in Phase 2 Clinical Trial of A-101 for Treatment of Common Warts
    Jul 30, 2016: Cytovation granted EU patent for its lead product, CyPep-1, for the treatment of cutaneous warts
    Jul 21, 2016: RXi Pharmaceuticals to Present at the 2016 Summer Meeting of the American Academy of Dermatology
    May 10, 2016: Novan to Present Anti-viral Data for Nitric Oxide Product Candidate SB206
    Dec 21, 2015: RXi Pharmaceuticals Announces the Initiation of a Phase 2 Trial in Dermatology with Samcyprone for Cutaneous Warts
    Dec 07, 2015: Aclaris Therapeutics Initiates Phase 2 Clinical Trial of A-101 for Treatment of Common Warts
    May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA
    May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA
    Oct 26, 2012: South Africa, first to grant IP protection in anti-warts
    May 07, 2003: Henderson Morley: Signed Licensing Agreement
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Warts, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Warts - Pipeline by 3M Drug Delivery Systems, H1 2017
    Warts - Pipeline by Aclaris Therapeutics Inc, H1 2017
    Warts - Pipeline by Agilvax Inc, H1 2017
    Warts - Pipeline by Aviragen Therapeutics Inc, H1 2017
    Warts - Pipeline by Biogenomics Ltd, H1 2017
    Warts - Pipeline by BioMAS Ltd, H1 2017
    Warts - Pipeline by Cutanea Life Sciences Inc, H1 2017
    Warts - Pipeline by Cytovation AS, H1 2017
    Warts - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
    Warts - Pipeline by G&E Herbal Biotechnology Co Ltd, H1 2017
    Warts - Pipeline by Laboratories Ojer Pharma SL, H1 2017
    Warts - Pipeline by LEO Pharma A/S, H1 2017
    Warts - Pipeline by Nielsen Biosciences Inc, H1 2017
    Warts - Pipeline by Novan Inc, H1 2017
    Warts - Pipeline by Novartis AG, H1 2017
    Warts - Pipeline by Promius Pharma LLC, H1 2017
    Warts - Pipeline by RXi Pharmaceuticals Corp, H1 2017
    Warts - Pipeline by Tamir Biotechnology Inc, H1 2017
    Warts - Pipeline by Verrica Pharmaceuticals Inc, H1 2017
    Warts - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
    Warts - Dormant Projects, H1 2017
    Warts - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Warts, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    3M Drug Delivery Systems
    Aclaris Therapeutics Inc
    Agilvax Inc
    Aviragen Therapeutics Inc
    Biogenomics Ltd
    BioMAS Ltd
    Cutanea Life Sciences Inc
    Cytovation AS
    Foamix Pharmaceuticals Ltd
    G&E Herbal Biotechnology Co Ltd
    Laboratories Ojer Pharma SL
    LEO Pharma A/S
    Nielsen Biosciences Inc
    Novan Inc
    Novartis AG
    Promius Pharma LLC
    RXi Pharmaceuticals Corp
    Tamir Biotechnology Inc
    Verrica Pharmaceuticals Inc
    Zydus Cadila Healthcare Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//warts-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//warts-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//warts-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments